Why is Moderna so Cheap?

Vaccines aren’t the only MRNA opportunity.

Andrew Willis 11 March, 2022 | 4:28AM
Facebook Twitter LinkedIn

 

 

Andrew Willis: As the potential end to the pandemic gets closer and closer, we’re raising our fair value estimate for Moderna (MRNA) more than 10%... Why?

Where’s the upside? We won’t need vaccines after this is all over, right? Well, sector strategist Karen Andersen has her sights on this Fall – and beyond, with the possibility of future variants emerging, antibody levels waning, and another booster shot needed.

After all this work on mRNA technologies, investors should remember that Moderna’s technology is still largely unproven – which means uncertainty, but also broad potential beyond vaccines. From oncology to rare diseases, it’s worth keeping an eye on the 25 other drug development candidates.

For Morningstar, I’m Andrew Willis.

Get the Latest Stock Insights in Your Inbox

Subscribe Here

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar Rating
Moderna Inc137.62 USD1.01Rating

About Author

Andrew Willis

Andrew Willis  is Senior Editor at Morningstar.ca. Follow him on Twitter @AndrewWillisCDN.

 

© Copyright 2022 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy